Trial ID or NCT#

NCT02031419

Status

not recruiting iconNOT RECRUITING

Purpose

First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma

Official Title

A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Ranjana Advani
Ranjana Advani
Medical oncologist, Lymphoma specialist
Saul A. Rosenberg, MD, Professor of Lymphoma
Lauren Maeda
Lauren Maeda
Clinical Associate Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology
Hans-Christoph Becker, MD, FSABI, FSCCT
Radiologist
Clinical Professor, Radiology

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061